Investor Presentaiton
Key highlights:
Continued growth momentum across key businesses
Strong Financial
1
Performance
Overall
Adj.
Revenues:
9%
(Q3 YoY Growth)
India Rx
-18.5%
EBITDA: (Adjusted for overhead
India Gx
Cipla
charge on FG inventory
movement in Q3 - ~120bps)
South Africa
20%
13%
Q3 YoY Growth
(Private
Market, Q3
YoY Growth;
ZAR)
Continued growth
2
across key markets
14%
7%
(Q3 YoY Growth)
(Q3 YoY Growth)
Momentum continues in
3
the US business
US$133mn
Q3 Revenues
13%
Q3 YoY Growth
Retained share in key product
categories
4
R&D and
Pipeline Progress
◉
5 Quality and Compliance
Q3 R&D at INR 308cr or ~7% to sales;
Respiratory trials well on-track for Advair
Establishment Inspection Report (EIR) received for Invagen and Patalganga
indicating closure of inspection
■ US FDA audit at Bangalore API facility ended with procedural observations
Closely working with US FDA to comprehensively address Goa observations
Investor Presentation: Q3FY20
4View entire presentation